200 related articles for article (PubMed ID: 35963129)
1. Structure-Activity relationship study of benzothiophene oxobutanoic acid analogues leading to novel stimulator of interferon gene (STING) agonists.
Shen A; Li X; Zhang Y; Ma J; Xiao R; Wang X; Song Z; Liu Z; Geng M; Zhang A; Xie Z; Ding C
Eur J Med Chem; 2022 Nov; 241():114627. PubMed ID: 35963129
[TBL] [Abstract][Full Text] [Related]
2. Structure-Activity Relationship Study of Amidobenzimidazole Analogues Leading to Potent and Systemically Administrable Stimulator of Interferon Gene (STING) Agonists.
Song Z; Wang X; Zhang Y; Gu W; Shen A; Ding C; Li H; Xiao R; Geng M; Xie Z; Zhang A
J Med Chem; 2021 Feb; 64(3):1649-1669. PubMed ID: 33470814
[TBL] [Abstract][Full Text] [Related]
3. Blocking Tim-3 enhances the anti-tumor immunity of STING agonist ADU-S100 by unleashing CD4
Luo J; Pang S; Hui Z; Zhao H; Xu S; Yu W; Yang L; Sun Q; Hao X; Wei F; Wang J; Ren X
Theranostics; 2023; 13(14):4836-4857. PubMed ID: 37771774
[No Abstract] [Full Text] [Related]
4. Structure-activity relationship study of amidobenzimidazole derivatives as stimulator of interferon genes (STING) agonists.
Liu X; Wang M; Yang M; Sun H; Wang B; Pan X; Chen X; Jin J; Wang X
Eur J Med Chem; 2023 Jan; 246():114943. PubMed ID: 36462438
[TBL] [Abstract][Full Text] [Related]
5. Discovery of novel Thieno[2,3-d]imidazole derivatives as agonists of human STING for antitumor immunotherapy using systemic administration.
Niu J; Bai H; Li Z; Gao Y; Zhang Y; Wang X; Yang Y; Xu Y; Geng M; Xie Z; Zhou B
Eur J Med Chem; 2022 Aug; 238():114482. PubMed ID: 35671593
[TBL] [Abstract][Full Text] [Related]
6. A next-generation STING agonist MSA-2: From mechanism to application.
Yang J; Luo Z; Ma J; Wang Y; Cheng N
J Control Release; 2024 Jul; 371():273-287. PubMed ID: 38789087
[TBL] [Abstract][Full Text] [Related]
7. Development of Potent Immune Modulators Targeting Stimulator of Interferon Genes Receptor.
Jeon MJ; Lee H; Lee J; Baek SY; Lee D; Jo S; Lee JY; Kang M; Jung HR; Han SB; Kim NJ; Lee S; Kim H
J Med Chem; 2022 Apr; 65(7):5407-5432. PubMed ID: 35315650
[TBL] [Abstract][Full Text] [Related]
8. Discovery of novel amidobenzimidazole derivatives as orally available small molecule modulators of stimulator of interferon genes for cancer immunotherapy.
Jeon MJ; Lee H; Jo S; Kang M; Jeong JH; Jeong SH; Lee JY; Song GY; Choo H; Lee S; Kim H
Eur J Med Chem; 2023 Dec; 261():115834. PubMed ID: 37862818
[TBL] [Abstract][Full Text] [Related]
9. Antagonism of regulatory ISGs enhances the anti-melanoma efficacy of STING agonists.
Filderman JN; Taylor JL; Wang J; Zhang Y; Singh P; Ross MA; Watkins SC; Nedal Al Bzour A; Karapetyan L; Kalinski P; Storkus WJ
Front Immunol; 2024; 15():1334769. PubMed ID: 38312842
[TBL] [Abstract][Full Text] [Related]
10. SHR1032, a novel STING agonist, stimulates anti-tumor immunity and directly induces AML apoptosis.
Song C; Liu D; Liu S; Li D; Horecny I; Zhang X; Li P; Chen L; Miller M; Chowdhury R; Issa M; Shen R; Yan Y; Zhang F; Zhang L; Zhang L; Bai C; Feng J; Zhuang L; Zhang R; Li J; Wilkinson H; Liu J; Tao W
Sci Rep; 2022 May; 12(1):8579. PubMed ID: 35595822
[TBL] [Abstract][Full Text] [Related]
11. Tumor Regression upon Intratumoral and Subcutaneous Dosing of the STING Agonist ALG-031048 in Mouse Efficacy Models.
Jekle A; Thatikonda SK; Jaisinghani R; Ren S; Kinkade A; Stevens SK; Stoycheva A; Rajwanshi VK; Williams C; Deval J; Mukherjee S; Zhang Q; Chanda S; Smith DB; Blatt LM; Symons JA; Gonzalvez F; Beigelman L
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003463
[TBL] [Abstract][Full Text] [Related]
12. STING Activation and its Application in Immuno-Oncology.
Lian Y; Duffy KJ; Yang J
Curr Top Med Chem; 2019; 19(24):2205-2227. PubMed ID: 31642767
[TBL] [Abstract][Full Text] [Related]
13. Development of Orally Bioavailable Amidobenzimidazole Analogues Targeting Stimulator of Interferon Gene (STING) Receptor.
Chen NN; Zhang H; Zhu QS; Zeng T; Dai W; Zhou YL; Xin GF; Wu BD; Gong SJ; Jiang ZY; You QD; Xu XL
J Med Chem; 2023 Apr; 66(8):5584-5610. PubMed ID: 37027512
[TBL] [Abstract][Full Text] [Related]
14. Identification of Novel Carbocyclic Pyrimidine Cyclic Dinucleotide STING Agonists for Antitumor Immunotherapy Using Systemic Intravenous Route.
Vyskocil S; Cardin D; Ciavarri J; Conlon J; Cullis C; England D; Gershman R; Gigstad K; Gipson K; Gould A; Greenspan P; Griffin R; Gulavita N; Harrison S; Hu Z; Hu Y; Hata A; Huang J; Huang SC; Janowick D; Jones M; Kolev V; Langston SP; Lee HM; Li G; Lok D; Ma L; Mai D; Malley J; Matsuda A; Mizutani H; Mizutani M; Molchanova N; Nunes E; Pusalkar S; Renou C; Rowland S; Sato Y; Shaw M; Shen L; Shi Z; Skene R; Soucy F; Stroud S; Xu H; Xu T; Abu-Yousif AO; Zhang J
J Med Chem; 2021 May; 64(10):6902-6923. PubMed ID: 34000802
[TBL] [Abstract][Full Text] [Related]
15. Discovery of Non-Nucleotide Small-Molecule STING Agonists
Cherney EC; Zhang L; Lo J; Huynh T; Wei D; Ahuja V; Quesnelle C; Schieven GL; Futran A; Locke GA; Lin Z; Monereau L; Chaudhry C; Blum J; Li S; Fereshteh M; Li-Wang B; Gangwar S; Pan C; Chong C; Zhu X; Posy SL; Sack JS; Zhang P; Ruzanov M; Harner M; Akhtar F; Schroeder GM; Vite G; Fink B
J Med Chem; 2022 Feb; 65(4):3518-3538. PubMed ID: 35108011
[TBL] [Abstract][Full Text] [Related]
16. Discovery of BI 7446: A Potent Cyclic Dinucleotide STING Agonist with Broad-Spectrum Variant Activity for the Treatment of Cancer.
Kuttruff CA; Fleck M; Carotta S; Arnhof H; Bretschneider T; Dahmann G; Gremel G; Grube A; Handschuh S; Heimann A; Hofmann MH; Impagnatiello MA; Nar H; Rast G; Schaaf O; Schmidt E; Oost T
J Med Chem; 2023 Jul; 66(14):9376-9400. PubMed ID: 37450324
[TBL] [Abstract][Full Text] [Related]
17. The Development of STING Agonists and Emerging Results as a Cancer Immunotherapy.
Hines JB; Kacew AJ; Sweis RF
Curr Oncol Rep; 2023 Mar; 25(3):189-199. PubMed ID: 36705879
[TBL] [Abstract][Full Text] [Related]
18. An updated patent review of stimulator of interferon genes agonists (2021 - present).
Xin GF; Chen NN; Li LL; Liu XC; Che CC; Wu BD; You QD; Xu XL
Expert Opin Ther Pat; 2024 May; 34(5):297-313. PubMed ID: 38849323
[TBL] [Abstract][Full Text] [Related]
19. STimulator of INterferon Genes Agonism Accelerates Antitumor Activity in Poorly Immunogenic Tumors.
Perera SA; Kopinja JE; Ma Y; Muise ES; Laskey J; Chakravarthy K; Chen Y; Cui L; Presland J; Sathe M; Javaid S; Minnihan EC; Ferguson HM; Piesvaux J; Pan BS; Zhao S; Sharma SK; Woo HC; Pucci V; Knemeyer I; Cemerski S; Cumming J; Trotter BW; Tse A; Khilnani A; Ranganath S; Long BJ; Bennett DJ; Addona GH
Mol Cancer Ther; 2022 Feb; 21(2):282-293. PubMed ID: 34815361
[TBL] [Abstract][Full Text] [Related]
20. STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade.
Yang H; Lee WS; Kong SJ; Kim CG; Kim JH; Chang SK; Kim S; Kim G; Chon HJ; Kim C
J Clin Invest; 2019 Jul; 129(10):4350-4364. PubMed ID: 31343989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
